Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 5/2015

01-05-2015 | Letter to the Editor

Clinical factors predictive of myelofibrotic evolution in patients with polycythemia vera

Authors: Mario Tiribelli, Daniela Barraco, Federico De Marchi, Luciana Marin, Marta Medeot, Daniela Damiani, Renato Fanin

Published in: Annals of Hematology | Issue 5/2015

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Stein RL, Moliterno AR, Tiu RV (2014) Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options. Ann Hematol 93:1965–1976CrossRefPubMed
2.
Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, Marilus R, Villegas A, Tognoni G, Barbui T (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23(10):2224–2232CrossRefPubMed
3.
Passamonti F, Rumi E, Caramella M, Elena C, Arcaini L, Boveri E, Del Curto C, Pietra D, Vanelli L, Bernasconi P, Pascutto C, Cazzola M, Morra E, Lazzarino M (2008) A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood 111(7):3383–3387CrossRefPubMed
4.
Bai J, Xue Y, Ye L, Yao J, Zhou C, Shao Z, Qian L, Yang R, Li H, Zhang H, Zheng Y (2008) Risk factors of long-term incidences of thrombosis, myelofibrosis and evolution into malignance in polycythemia vera: a single center experience from China. Int J Hematol 88(5):530–535CrossRefPubMed
5.
Alvarez-Larrán A, Bellosillo B, Martínez-Avilés L, Saumell S, Salar A, Abella E, Gimeno E, Serrano S, Florensa L, Sánchez B, Pedro C, Besses C (2009) Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients. Br J Haematol 146(5):504–509CrossRefPubMed
6.
Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L, Roncoroni E, Astori C, Merli M, Boggi S, Pascutto C, Lazzarino M, Cazzola M (2010) A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 24(9):1574–1579CrossRefPubMed
7.
Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Barosi G, Verstovsek S, Birgegard G, Mesa R, Reilly JT, Gisslinger H, Vannucchi AM, Cervantes F, Finazzi G, Hoffman R, Gilliland DG, Bloomfield CD, Vardiman JW (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110(4):1092–1097CrossRefPubMed
8.
Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S, Dupriez B, Levine RL, Passamonti F, Gotlib J, Reilly JT, Vannucchi AM, Hanson CA, Solberg LA, Orazi A, Tefferi A, International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) (2008) Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 22(2):437–438CrossRefPubMed
9.
Metadata
Title
Clinical factors predictive of myelofibrotic evolution in patients with polycythemia vera
Authors
Mario Tiribelli
Daniela Barraco
Federico De Marchi
Luciana Marin
Marta Medeot
Daniela Damiani
Renato Fanin
Publication date
01-05-2015
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 5/2015
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-014-2257-z

Other articles of this Issue 5/2015

Annals of Hematology 5/2015 Go to the issue

Letter to the Editor

Remission induction with lenalidomide in a patient with relapsed diffuse large B cell lymphoma of the leg type

Original Article

The JAK2 46/1 haplotype does not predispose to CALR-mutated myeloproliferative neoplasms

Original Article

Efficacy of porcine antihuman lymphocyte immunoglobulin compared to rabbit antithymocyte immunoglobulin as a first-line treatment against acquired severe aplastic anemia

Original Article

Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications

Original Article

Prolonged clinical remissions in patients with relapsed or refractory follicular lymphoma treated with autologous stem cell transplantation incorporating rituximab

Letter to the Editor

Calreticulin mutations are not present in patients with myeloproliferative chronic myelomonocytic leukemia

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits